HIV treatment


CROI2022 overview w/Dr. Carl Dieffenbach, head of NIAID NIAID director Dr. Carl Dieffenbach reviews updates from #CROI2022 (www.croiconference.org) in this 34-minute video. In an HIV.gov video conversation on Wednesday, February 16, NIH’s Dr. Carl Dieffenbach discussed some of the pivotal HIV research advances presented this week at the 2022 virtual […]

NIH’s Dr. Carl Dieffenbach Discusses Highlights of HIV Cure, Treatment ...


Participant Summary Click here for a printable participant summary.   Title: A5355 – Phase II, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-based anti-Cytomegalovirus (CMV) Vaccine (Triplex®), in Adults with Both Human Immunodeficiency Virus (HIV)-1 and CMV Who Are on Potent Combination ART […]

A5355: a clinical trial of an anti-CMV vaccine



Title: A5391: Doravirine for Persons with Excessive Weight Gain while taking Integrase Inhibitors and Tenofovir Alafenamide (TAF): The DO-IT Study Click here for printable participant summary. Description: Weight gain after starting anti-HIV medicines is common, but recent studies have found that taking certain medicines may cause increased weight more than […]

A5391: Doravirine for Persons with Excessive Weight Gain on Integrase ...


Title: A5386: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control in the Reservoirs During Analytic Treatment Interruption Purpose: Researchers are looking for ways to get rid of HIV that rests hidden in areas of the body (reservoirs) where current […]

A5386, a clinical trial to control HIV in a new ...